Xenomics, Inc. (Xenomics), a developer of trans-renal molecular diagnostic technologies, has appointed Bruce A. Huebner as chief executive officer (CEO) and board director.
Huebner has over 35 years of experience in the diagnostic industry, and has been worked for number of clinical diagnostic companies including Hybritech, Inc., Gen-Probe, Inc., Nanogen, Inc. and Osmetech Molecular Diagnostics. From 1996 to 2002, he was executive vice president and chief operating officer of Gen-Probe, Inc. Huebner was president and chief operating officer of Nanogen, Inc. From 2005 to 2008, Huebner, as president of Osmetech, successfully established Osmetech as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace.